Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Pionyr Immunotherapeutics, Inc., now a Gilead company, was a clinical-stage immuno-oncology company focused on developing a new generation of antibody-based therapeutics. Their innovative Myeloid Tuning™ approach aimed to alter the tumor microenvironment by reprogramming myeloid cells to enhance anti-tumor immunity. Pionyr's research centered on identifying and targeting novel immune regulatory mechanisms within the tumor stroma, with the goal of providing durable and clinically meaningful responses for cancer patients. The company was acquired by Gilead Sciences in June 2020 to bolster Gilead's immuno-oncology pipeline.
Served as the company's primary hub for research and development (R&D), clinical operations, and corporate administration, focusing on advancing their Myeloid Tuning™ platform.
Located in a modern biotech park, likely equipped with advanced laboratory facilities suitable for antibody development and cancer research. Sierra Point is known for hosting numerous life science companies.
As a biotech startup, Pionyr likely fostered a dynamic, science-driven, and collaborative environment with a strong emphasis on innovation, research excellence, and a mission-driven approach to cancer therapy.
The Brisbane headquarters was significant as the birthplace of Pionyr's Myeloid Tuning™ platform and the center of its efforts to develop novel cancer immunotherapies. Following its acquisition by Gilead, its assets and programs were integrated into Gilead's global R&D operations.
As a focused biotechnology company prior to its acquisition by Gilead, Pionyr Immunotherapeutics' primary operations were centered in the United States. Its research and development efforts, while aimed at addressing global health challenges in oncology, were largely conducted from its California headquarters. Post-acquisition, its programs and technologies became part of Gilead's global oncology efforts.
2000 Sierra Point Parkway, Suite 600
Brisbane
CA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Pionyr Immunotherapeutics' leadership includes:
Pionyr Immunotherapeutics has been backed by several prominent investors over the years, including:
In the 12-18 months leading up to its acquisition by Gilead in June 2020, Pionyr Immunotherapeutics saw a key leadership appointment. Following the acquisition, its executive team transitioned as operations were integrated into Gilead.
Discover the tools Pionyr Immunotherapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Prior to its acquisition by Gilead, Pionyr Immunotherapeutics likely used standard corporate email formats for its domain pionyrtx.com. While specific patterns are not publicly confirmed, a common format for companies of its type and size is the first initial followed by the last name.
[first_initial][last]@pionyrtx.com
Format
jdoe@pionyrtx.com (example for illustrative purposes)
Example
0 (domain inactive post-acquisition)%
Success rate
Gilead Sciences • June 23, 2020
Gilead Sciences announced the completion of its acquisition of Pionyr Immunotherapeutics Inc., a privately held company developing cancer immunotherapies that target myeloid cells. The acquisition adds Pionyr's pipeline programs, including PY314 and PY159, to Gilead's immuno-oncology portfolio....more
Business Wire (on behalf of Pionyr Immunotherapeutics) • April 2, 2020
Pionyr Immunotherapeutics announced an agreement with Gilead Sciences, Inc. under which Gilead acquired a 49.9 percent equity interest in Pionyr and an exclusive option to acquire the remainder of Pionyr. The collaboration focused on advancing PY314 and PY159, first-in-class antibody programs....more
FierceBiotech • November 6, 2019
Pionyr Immunotherapeutics hired Leonard Post, Ph.D., as its new chief scientific officer. Post previously served as CSO at Achaogen. Pionyr also announced a manufacturing deal with Ichnos Sciences for its lead programs PY314 and PY159....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Pionyr Immunotherapeutics, are just a search away.